Frontiers in Pharmacology Submission Guide

Submit to Frontiers in Pharmacology if the manuscript's center of gravity is pharmacology: drug action, pharmacodynamics, pharmacokinetics, therapeutic mechanism, toxicology, clinical pharmacology, pharmacogenomics, drug safety, outcomes, or policy that belongs in one of the journal's sections.

Think twice if the paper is mainly:

• a disease-biology story with a drug name attached late
• a medicinal-chemistry synthesis paper without enough pharmacological testing
• a clinical outcome study with little pharmacology interpretation
• an omics screen that never connects back to drug action, response, toxicity, or mechanism
• a review that fits a broader medical or biological journal better than a Frontiers pharmacology section

Frontiers-style pharmacology papers usually fail for section mismatch before they fail for formatting. Authors can often list the journal, but they cannot name the exact section and editor audience the paper should satisfy. That is a warning sign.

Frontiers says authors submit to the specialty section that best covers the research area. For Frontiers in Pharmacology, that matters more than many authors expect.

A manuscript can be a reasonable pharmacology paper and still feel wrong for the section selected in the portal. A clinical pharmacology paper, a drug-safety study, a neuropharmacology experiment, a pharmacogenomics analysis, and a policy/outcomes paper do not ask the same reviewer pool to make the same judgment.

Use this test before upload:

If you cannot answer the section-fit question in one sentence, the paper is not ready for upload.

Across our Frontiers in Pharmacology pre-submission reviews, the strongest predictor of a clean first read is not whether the paper uses the word "pharmacology." It is whether the manuscript makes three components visible together: the pharmacological object, the section audience, and the evidence boundary.

In our pre-submission review work, we see this as a specific failure pattern rather than a formatting problem. Manusights internal analysis of Frontiers-style pharmacology manuscripts treats the editorial triage pattern as a first-page fit test: title, abstract, section choice, first figure, methods, limitations, and cover note have to point to the same pharmacology question.

The Frontiers in Pharmacology section-without-a-section paper names the journal but leaves the editor guessing whether the work belongs in clinical pharmacology, drug safety, neuropharmacology, pharmacogenomics, experimental pharmacology, or policy. The first-page symptom is usually visible in the abstract, keywords, and cover note: they list a disease or assay but do not name the specialty-section reader who should handle the paper. Check whether your Frontiers in Pharmacology section choice is defensible →

The Frontiers in Pharmacology mechanism-without-pharmacology paper shows a pathway, phenotype, or omics signal but never proves that drug action, exposure, response, toxicity, receptor logic, or target engagement is the actual contribution. The weak version hides this in the methods and first figure: the assay is real, but the pharmacological object is not load-bearing. Reviewers then treat the work as disease biology with a compound attached. Check if your pharmacology claim is strong enough →

The Frontiers in Pharmacology evidence-boundary paper has promising data but phrases an in vitro, animal, association, or network result as if it already supports a clinical or therapeutic claim. The warning signs are concrete: the discussion uses treatment language before toxicity is characterized, the conclusion outruns the model system, or the limitations section does not name exposure, confounding, sample size, validation, or translation limits. Check whether your claims outrun your evidence →

The pharmacological object is the thing being judged. That may be a drug, target, receptor, pathway, exposure, formulation, safety signal, or prescribing decision. Weak manuscripts mention the object but let the real story become broad disease biology. Stronger manuscripts make the object carry the argument from the title through the first results display.

The section audience is the editor and reviewer community the paper is asking Frontiers to assemble. We often see authors choose Frontiers in Pharmacology because it feels broad and accessible, then leave the section choice to the portal. That is backwards. If the abstract could plausibly go to three different sections, the manuscript usually needs a narrower opening claim before upload.

The evidence boundary is the limit of what the data can honestly support. Pharmacology reviewers are sensitive to overreach: in vitro potency framed as therapeutic promise, observational association framed as drug effect, animal exposure framed as clinical safety, or network pharmacology framed as mechanism without enough validation. Those are not formatting problems. They are claim-discipline problems.

The useful Manusights test is simple: if an associate editor reads only the title, abstract, first figure, and section choice, can they tell what pharmacological question the paper answers and what it does not answer? If not, the upload package is not ready even if every portal field is complete.

These patterns are fixable before upload, but they are hard to repair after an editor has already routed the manuscript to the wrong reviewer pool. The review tells you whether your paper passes that first-read test before submission. Reviews include a 60-day money-back guarantee, and we do not train AI models on your manuscript.

Check whether your Frontiers in Pharmacology section choice is defensible →

Frontiers in Pharmacology publishes multiple article types, and the official article-types page gives different expectations by type. Original Research, Clinical Trial, Review, Mini Review, Perspective, Case Report, Hypothesis and Theory, and policy-oriented formats do not carry the same word limits, display-item expectations, or evidence standard.

For example, the current article-type page lists 12,000-word caps for Clinical Trial and Hypothesis and Theory articles, while Mini Reviews and Perspectives are capped at 3,000 words with no more than 2 figures or tables, and Case Reports are capped at 3,000 words with no more than 4 display items. Check the live article-type page for your selected format before upload.

That means the article type is not a clerical choice. It tells reviewers what kind of evidence they should expect.

Common mismatches:

• Original Research chosen for a mostly exploratory screen. Reviewers expect a full pharmacology argument, not only a signal-generation exercise.
• Review chosen for a literature catalog. A review needs a critical thesis about drug action, therapeutic strategy, safety, or policy.
• Case Report chosen for an ordinary clinical event. The report needs a pharmacological lesson that travels beyond one patient.
• Clinical Trial chosen without trial-readiness details. Registration, ethics, intervention logic, endpoints, and limitations need to be clear before upload.

Before submission, read the article-type page for the specific format and verify the live word, figure, and structure limits. Do not rely on old templates or third-party format summaries.

Frontiers' public materials emphasize specialty sections, external editors, peer review, publication ethics, author contributions, and open-access publication. The Manusights layer is how those facts translate into an editor's first read.

Editors are likely to ask:

• Does the manuscript belong in this specialty section?
• Is the pharmacology question central enough?
• Does the evidence support the therapeutic, mechanistic, safety, or clinical claim?
• Are ethics, consent, data, and competing-interest statements complete?
• Is the paper an article-type match, or is it being squeezed into the wrong format?

For pharmacology manuscripts, the cleanest first read usually has one visible through-line: compound, target, pathway, exposure, response, safety signal, or patient-relevant pharmacological decision. If the manuscript only becomes pharmacology after several pages of background, it is exposed.

Frontiers publishes the broad process rather than a single guaranteed decision clock. Treat the timeline below as a planning model, not a promise.

Day 0: submission package enters Frontiers

The submitting author selects Frontiers in Pharmacology, article type, specialty section, author details, declarations, and files. This is where section-fit mistakes become visible.

Days 1 to 7: technical and editorial intake

The package can slow down if author contributions, ethics, consent, funding, data availability, conflict statements, figures, or supplementary files are incomplete.

Week 2: specialty-section and editor fit

The handling route depends on whether the title, abstract, keywords, cover note, and section choice point to the same pharmacology question.

Weeks 3 to 8: reviewer invitation and review

Reviewers test the pharmacology claim, evidence boundary, and article-type match. If the manuscript is really disease biology, chemistry, or general clinical research, that mismatch surfaces here.

Week 9 onward: editorial synthesis or revision dialogue

The editor either has a coherent revision path or has to resolve a section/evidence mismatch that should have been fixed before upload.

Across Manusights reviews of pharmacology and biomedical manuscripts, the weak Frontiers in Pharmacology submissions usually fit one of four patterns.

The section is named too late. The authors know the journal but not the section. That creates a vague cover letter, weak keywords, and an abstract that does not tell the associate editor why this reviewer community should handle the paper.

Pharmacology is decorative. The manuscript is really molecular biology, disease biology, public health, or chemistry, with a drug or target mentioned as context. Reviewers can see when the pharmacological mechanism is not load-bearing.

Evidence and article type do not match. A short case, exploratory model, narrative review, or preliminary screen is submitted as if it carries a stronger article type. The editor has to downgrade the claim before peer review can even start.

The integrity package is incomplete. Human or animal ethics, consent, clinical-trial information, data availability, author contributions, or conflict statements are vague. Frontiers' checklist makes these visible during submission, so weak answers feel like manuscript-readiness problems.

The Frontiers process is linear: prepare, register, submit, select the specialty area, complete metadata and declarations, upload files, and move through editorial and peer review. The portal helps organize that work, but the editorial decision still depends on whether the manuscript reads like it belongs in the selected pharmacology section.

Practical sequence:

1. Confirm journal and section fit.
2. Confirm article type and current limits.
3. Build the ethics, data, funding, conflicts, and author-contribution package.
4. Check whether the title and abstract make the pharmacology claim visible.
5. Upload only after the files and declarations tell one consistent story.

That order matters. If you start with formatting, you may finish a clean file for the wrong section.

Do not choose this journal only because Frontiers has a large open-access platform or because the word "pharmacology" appears somewhere in the manuscript.

Choose another target if:

• the core result is medicinal chemistry synthesis rather than pharmacological evidence
• the strongest audience is a narrow disease specialty
• the clinical claim is better judged by a clinical-trial or outcomes journal
• the study is mainly toxicology, public health, or policy without a strong pharmacology center
• the APC model is a problem and your institution does not cover fees

Frontiers may still be a good publisher route for many authors, but the journal choice should come from manuscript fit, not convenience.